Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Investing.com - Bernstein SocGen Group raised its price target on BeOne Medicines (NASDAQ:ONC) to $362.00 from $259.00 while maintaining a Market Perform rating. The stock, currently trading at $351.09, sits near its 52-week high of $355.30, having delivered an impressive 70.17% return over the past six months. According to InvestingPro data, analyst targets for BeOne range from $250 to $563.
The firm increased its total estimates on BeOne’s three B-cell products from $8 billion to $10 billion, with Zanu at $5 billion, Sonro at $3 billion, and BGB-16673 at $2 billion.
Bernstein noted that Zanu’s share in the US BTKi market reached 28% by Q2 2025, up from 24% in Q2 2024. The firm estimates Zanu’s global market share will reach 25% in 2025 and grow to 35% by 2027, generating $4.7 billion in sales.
The firm highlighted that BeOne’s sonrotoclax + zanu combination therapy shows better efficacy and safety compared to current standard therapies, with Grade 3 or above treatment-related adverse events at 45-57% versus approximately 80% for venetoclax combinations.
Bernstein updated its valuation approach to average DCF, P/S, and terminal P/E (2030E) methods, using 6.7x and 25x as the respective multiples, resulting in the new $362 price target.
In other recent news, BeOne Medicines has been in the spotlight with several significant developments. The company announced positive topline results from a Phase 1/2 study of sonrotoclax in patients with relapsed/refractory mantle cell lymphoma, meeting its primary endpoint of overall response rate. This follows the European Commission’s approval of TEVIMBRA for the treatment of resectable non-small cell lung cancer, demonstrating significant overall survival benefits in the Phase 3 RATIONALE-315 trial. Barclays initiated coverage on BeOne Medicines with an Overweight rating, citing upcoming pivotal data readouts that could drive growth, while Citizens JMP reiterated its Market Outperform rating with a price target of $348.00.
Meanwhile, Oncolytics Biotech unveiled the design for its upcoming pancreatic cancer registration trial. The trial will feature a three-arm design, where patients will receive either standard chemotherapy, chemotherapy combined with pelareorep, or chemotherapy with both pelareorep and a checkpoint inhibitor. This announcement comes ahead of a scheduled meeting with the U.S. Food and Drug Administration in mid-November 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.